The largest database of trusted experimental protocols
> Procedures > Diagnostic Procedure > Blood Glucose Self-Monitoring

Blood Glucose Self-Monitoring

Blood Glucose Self-Monitoring: The process of measuring and monitoring one's own blood glucose levels.
This involves the use of portable devices and home testing kits to frequently check blood sugar levels, enabling individuals with diabetes or other conditions to manage their condition more effectively.
By optimizing this process through AI-driven research platforms like PubCompare.ai, users can enhance reproducibility, accuracy, and informed decision-making, streamlining their glucose monitoring and improving overall health outcomes.

Most cited protocols related to «Blood Glucose Self-Monitoring»

Women were invited to participate in this study if, between 24 weeks 0 days and 30 weeks 6 days of gestation, they had a blood glucose concentration between 135 and 200 mg per deciliter (between 7.5 and 11.1 mmol per liter) 1 hour after a 50-g glucose loading test. Women were excluded if they had preexisting diabetes, an abnormal result on a glucose screening test before 24 weeks of gestation, prior gestational diabetes, a history of stillbirth, multifetal gestation, asthma, or chronic hypertension; if they were taking corticosteroids; if there was a known fetal anomaly; or if imminent or preterm delivery was likely because of maternal disease or fetal conditions. All the women who pa rticipated in the study provided written informed consent. The study was approved by the human subjects committee at each participating center.
After an overnight fast, eligible women completed a blinded 3-hour 100-g oral glucose-tolerance test. Samples were analyzed at a central laboratory, and results were forwarded to the data coordinating center. Mild gestational diabetes mellitus was defined as a fasting glucose level of less than 95 mg per deciliter (5.3 mmol per liter) and two or three timed glucose measurements that exceeded established thresholds: 1-hour, 180 mg per deciliter (10.0 mmol per liter); 2-hour, 155 mg per deciliter (8.6 mmol per liter); and 3-hour, 140 mg per deciliter (7.8 mmol per liter).10 (link) Women who met these criteria were randomly assigned by the coordinating center, with the use of the simple urn method,11 (link) stratified by clinical center. The urn method minimizes the degree of imbalance in the number of patients assigned to each group by increasing the probability of a patient’s assignment to the group that has previously been selected least often. Women were assigned to receive either formal nutritional counseling and diet therapy,12 (link) along with insulin if required (treatment group) or usual prenatal care (control group). In addition, a cohort of women who had a positive result on the 50-g glucose loading test but a normal result on a subsequent oral glucose-tolerance test and who were matched with the study cohort according to race and body-mass index (the weight in kilograms divided by the square of the height in meters), dichotomized as less than 27 or 27 or more, were enrolled by the data coordinating center in the group that received usual prenatal care. By including this group of women who did not have gestational diabetes mellitus, the patients, their caregivers, and the study staff were unaware of whether women in the control group met the criteria for the diagnosis of mild gestational diabetes mellitus. Women with a fasting glucose level of 95 mg per deciliter or more on the diagnostic oral glucose-tolerance test were excluded from the study, and their condition was made known to their health care providers.
Ultrasonography was performed in all subjects before the oral glucose-tolerance test to confirm the gestational age. Women who were receiving treatment performed daily self-monitoring of their blood glucose (fasting and 2-hour postprandial measurements) with the use of a portable memory-based reflectance meter. Insulin was prescribed if the majority of fasting values or postprandial values between study visits were elevated (fasting glucose level, ≥95 mg per deciliter or 2-hour postprandial glucose level, ≥120 mg per deciliter [6.7 mmol per liter]). If, during a prenatal visit, there was a clinical suspicion of hyperglycemia in a patient who was in the control group, the blood glucose level could be measured at the discretion of the provider. If a random blood glucose level of 160 mg per deciliter (8.9 mmol per liter) or more or a fasting glucose level of 95 mg per deciliter or more was detected, the patient’s caregiver initiated treatment and notified the local principal investigator and study personnel.
Nonstress testing, biophysical profile testing, and ultrasonography to assess fetal growth were not performed routinely in the treatment group but were reserved for standard obstetrical indications. However, all the women who were enrolled in the study were instructed regarding the daily assessment of fetal activity.13 (link) If delivery was not the result of spontaneous labor, the rationale for the timing and method of delivery was documented.
Publication 2009
Adrenal Cortex Hormones Asthma Blood Glucose Blood Glucose Self-Monitoring Care, Prenatal Diabetes Mellitus Diagnosis Fetal Anomalies Fetal Diseases Fetal Growth Fetal Movement Gestational Age Gestational Diabetes Glucose High Blood Pressures Homo sapiens Hyperglycemia Index, Body Mass Insulin Memory Mothers Obstetric Delivery Obstetric Labor Oral Glucose Tolerance Test Patients Pregnancy Premature Birth Therapy, Diet Ultrasonography Woman
The DCCT design has been described elsewhere (1 (link)). Briefly, we recruited 1,441 subjects with 1–15 years duration of type 1 diabetes, minimal or no microvascular complications, and no history of neuropathy requiring medical treatment. Subjects were randomly assigned to intensive treatment (three or more insulin injections daily or continuous subcutaneous insulin infusion, guided by frequent self-monitoring of blood glucose) or conventional treatment (one or two insulin injections daily) and followed for 4–9 years (mean 6.5 years) (1 (link),9 (link)). The DCCT included a primary prevention cohort and a secondary intervention cohort. The primary prevention cohort had diabetes for 1–5 years (mean 2.6 years) and no retinopathy or microalbuminuria at baseline. The secondary intervention cohort had diabetes for 1–15 years (mean 8.7 years) and mild to moderate retinopathy at baseline. The secondary intervention cohort also had a higher prevalence of confirmed clinical neuropathy at DCCT baseline than the primary prevention cohort (9.4 vs. 3.5%, respectively) (8 (link)).
Of 1,305 subjects from the original DCCT cohort who were active in the EDIC study, 1,186 agreed to participate in NeuroEDIC. These included 603 in the former intensive treatment group and 583 in the former conventional treatment group, representing 93 and 91% of eligible participants, respectively.
Publication 2010
Blood Glucose Self-Monitoring Diabetes Mellitus Diabetes Mellitus, Insulin-Dependent Insulin Primary Prevention Retinal Diseases Subcutaneous Infusions
The primary outcome was change in HbA1c, defined as the difference between HbA1c prior to commencement of any flash monitoring and the next available value after the flash monitoring education session. We also report the proportion of individuals achieving the Scottish HbA1c target (<58 mmol/mol [7.5%]) and UK National Institute for Health and Care Excellence (NICE) target (≤48 mmol/mol [6.5%]) [6 ]. We obtained hospital admission and emergency department attendance data for the 6 months following NHS-funded flash monitor use and the corresponding 6 month period in the preceding 2 years. National prescribing database data were obtained for collected prescriptions for glucose test strips and sensors, over the same timescale described above. HbA1c, admission and prescribing data are presented for the entire cohort of flash monitor users from both participating hospitals (n = 900). Scottish Index of Multiple Deprivation 2016 (SIMD) rank and quintile were determined [7 ]. The structured education programme offered in our centre is Dose Adjustment for Normal Eating (DAFNE) [8 (link)] and previous participation was discerned from our national clinic database system, SCI-Diabetes (https://www.sci-diabetes.scot.nhs.uk). Mode of insulin delivery (multiple daily injection [MDI] or continuous subcutaneous insulin infusion [CSII]) was also obtained from SCI-Diabetes.
Additional data were collected in the subgroup of flash monitor users attending the RIE (n = 589): these included change in BMI, clinic questionnaire data, online questionnaire data and flash monitoring data. All individuals attending RIE diabetes clinics are asked to complete a form at each attendance (electronic supplementary material [ESM] Questionnaire 1) which includes hypoglycaemia questions (including Gold score and a modification of the Clarke assessment [9 (link)]), frequency of self-monitoring of blood glucose (SMBG), timing of bolus insulin and the Hospital Anxiety and Depression Scale (HADS) [10 (link)]. We report changes in hypoglycaemia and HADS score in those where paired pre- and post-flash monitoring questionnaires were available. In addition, all individuals attending RIE flash monitoring education events were sent an online questionnaire invitation 1 month after attendance (ESM Questionnaire 2). This included questions on satisfaction with flash monitoring and a modified version of the diabetes distress scale (DDS) [11 (link)]. Flash glucose data was obtained from the ‘LibreView’ portal (Freestyle Libre).
Publication 2019
Anxiety Blood Glucose Self-Monitoring Diabetes Mellitus Glucose Gold Hypoglycemia Insulin Obstetric Delivery Prescriptions Programmed Learning Satisfaction Subcutaneous Infusions
Glycemic status will be monitored with HbA1c determinations every 2–3 months in all participants. Participants randomized to insulin therapy and those with known diabetes will also perform self-monitoring of blood glucose and will be instructed regarding the signs and symptoms of hypoglycemia and hyperglycemia and when to contact the study team. If glucose control worsens unacceptably, participants will be scheduled for final outcome assessments as soon as possible, followed immediately thereafter by institution of clinically appropriate therapy according to their primary diabetes provider.
Publication 2014
Blood Glucose Self-Monitoring Diabetes Mellitus Glucose Hyperglycemia Hypoglycemia Insulin Therapeutics
Cost inputs for most healthcare resources were obtained from a cost analysis conducted in Spain on an ad hoc basis, and based upon input from health professionals [15 (link)]. For hospitalization, the cost per day was applied to an average stay of 8.0 days for patients with T1DM and 4.9 days for patients with T2DM, both of which were obtained from a retrospective study of patients with diabetes admitted to hospital for severe hypoglycemia [18 ]. The cost of an ambulance was obtained from the Regional Health Service of Castilla-León. The cost of an SMBG test strip was reported in the questionnaire-based study that informed many of the utilization inputs and the hypoglycemia rates [8 (link)]. The cost inputs are shown in Table 1.

Cost inputs

ResourceCost and reference
Ambulance€496.19
A&E€192.26 [15 (link)]
Hospitalization€442.81 per day [15 (link)]; patients with T1DM were assumed to stay for an average of 8.0 days, and patients with T2DM for an average of 4.9 days [18 ]
GP visit€65.66 [15 (link)]
Diabetes specialist visit€146.04 [15 (link)]
SMBG€0.25 [8 (link)]

A&E accident and emergency, GP general practitioner, SMBG self-monitoring of blood glucose, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus

Publication 2017
Accidents Ambulances Blood Glucose Self-Monitoring Diabetes Mellitus Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus, Non-Insulin-Dependent Emergencies Health Personnel Hospitalization Hypoglycemia Patients

Most recents protocols related to «Blood Glucose Self-Monitoring»

CGM measures glucose in interstitial fluid through subcutaneous sensor and saves data in the recorder every 5 minutes. It has been validated by several studies and was also known to provide a very well correlation between blood and interstitial fluid glucose values.[17 (link)] A minimum of 3 self-monitoring of blood glucose values per day from glucometer are needed to calibrate the glucose sensor data. CGM measurements provided several important information of GV, including time per day within target glucose range (time-in-range, glucose levels between 70–180 mg/dL), time-above target glucose range (time-above-range, glucose levels > 180 mg/dL), and time-below target glucose range (Time-Below-Range, glucose levels < 70 mg/dL). GV indices, which included standard deviation (SD), (magnitude of glycemic excursions [MAGE], average of blood glucose excursions exceeding 1 SD of the mean blood glucose value), (mean of daily differences [MODD], the absolute difference between the paired CGMS values obtained during 2 successive days (minimum and maximum SD days), and (continuous overall net glycemic action [CONGA], SD of differences between observed blood glucose reading and an observed blood glucose level).[18 (link),19 (link)]
Publication 2023
BLOOD Blood Glucose Blood Glucose Self-Monitoring Glucose Interstitial Fluid
All 93 patients underwent TP were followed up through the endocrinology clinic and telephone visits. Regular follow-up by the surgeon and the oncologist was performed simultaneously. Overall survival of the TP patients with different pathologies from surgery to the date of death or last follow-up was evaluated. Diabetes assessments were available in 80 patients after TP with relatively stable general conditions and primary diseases. Follow-up variables, including HbA1c, fasting C-peptide, creatinine, urinary albumin-to-creatinine ratio, and liver function, were measured in patients underwent TP. Hypoglycemia data were derived from self-monitoring of blood glucose profiles. Seven TP patients underwent CGM for seven days with calibration by 4-point self-monitoring of blood glucose to obtain mean glucose value, SD, CV, time in range (TIR), time above range (TAR), and time below range (TBR), etc. Weight, gastrointestinal symptoms, pancreatic enzymes dose, and events of diabetic chronic complications were recorded.
Publication 2023
Albumins Blood Glucose Self-Monitoring C-Peptide Complications of Diabetes Mellitus Creatinine Diabetes Mellitus Enzymes Glucose Hypoglycemia Liver Oncologists Pancreas Patients Surgeons System, Endocrine Urine
The dependent variable of this study was poor glycemic control whereas the independent variables were socio-demographic characteristics (age, sex, religion, marital status, residency, educational status, economic status, and occupation), lifestyle-related characteristics (exercise, alcohol drinking, and smoking), DM and comorbidity related characteristics (duration of DM, presence of comorbidities, and self-monitoring of blood glucose), anti-DM medication-related characteristics (types of anti-DM medications, duration of medications, and adherence to anti-DM medications) and physical examination (BP and BMI), and laboratory results (serum creatinine, proteinuria, serum high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, and triglyceride (TAG).
Publication 2023
Blood Glucose Self-Monitoring Cholesterol Creatinine Glycemic Control High Density Lipoproteins Low-Density Lipoproteins Pharmaceutical Preparations Physical Examination Residency Serum Triglycerides
The analysis was conducted from a third-party payer perspective (National Organization for Healthcare Services Provision [EOPYY]) and, therefore, only direct healthcare costs were included. The analysis aimed at comparing the lifetime costs and effects of empagliflozin versus branded sitagliptin. All prices used were euros (€).
Treatment costs considered in the analysis included drug cost, and needle and the costs associated with self-monitoring of blood glucose for patients receiving insulin (Table S5). Unit costs were sourced from the most recent price bulletin issued by the Greek Ministry of Health.37 For patients with established CVD, aside the main therapy (either empagliflozin or sitagliptin), also insulin as concomitant therapy was considered. The proportion of patients receiving insulin at baseline was considered in the calculation of first-year cost (48% for empagliflozin and 24% for sitagliptin). To estimate the cost of the following-up years, the proportion of patients receiving insulin at the end of trial was used (51% for empagliflozin and 33% for sitagliptin).
Other captured direct healthcare costs were diabetes-related complications (cardiovascular disease, renal, acute events, eye disease, neuropathy, foot ulcer and amputation), costs and patient management costs. Annual costs were obtained from published literature,20 (link),38 (link) and all costs were inflated to 2021 using the National Statistical Service.39
Table S6 summarized all the input costs used in the analysis.
Publication 2023
Amputation Blood Glucose Self-Monitoring Cardiovascular Diseases Complications of Diabetes Mellitus empagliflozin Eye Disorders Foot Ulcer Health Services, National Insulin Kidney Needles Patients Sitagliptin Therapeutics
The blinded CGM system was used to generate dynamic glucose profiles (iPro2 with Enlite sensor, Medtronic MiniMed, Northridge, CA, USA). The CGM system’s glucose sensor (MMT-7008A) was implanted on the lateral upper arm and removed after one week, generating a maximum daily record of 288 continuous sensor glucose measurements. Self-monitoring of blood glucose (SMBG) was required for the participants in order to calibrate CGMs at least four times/day. Then, the CGM data were exported and subjected to quality assessment. When at least 70% of the CGM data (5 valid days, equivalent to 1440 glucose readings) was available, the CGM parameters were calculated using M-Smart software (CareLink iPro) provided by Medtronic.
Publication 2023
Arm, Upper Blood Glucose Self-Monitoring Glucose

Top products related to «Blood Glucose Self-Monitoring»

Sourced in United States
The Enlite sensor is a medical device used for continuous glucose monitoring. It measures glucose levels in the body and provides real-time data to aid in the management of diabetes. The Enlite sensor is designed to be worn on the body and provides glucose readings without the need for finger prick blood samples.
Sourced in United States, Japan, Switzerland, Ireland
The iPro2 is a continuous glucose monitoring (CGM) system designed to measure and record glucose levels in patients. It consists of a small sensor that is inserted under the skin to measure glucose levels, and a recording device that collects the data. The iPro2 is intended to provide healthcare professionals with detailed glucose data to help manage their patients' diabetes.
Sourced in Japan
The Medisafe Mini is a compact and portable medical device designed for the safe collection and transportation of blood and other liquid samples. It is a part of Terumo's laboratory equipment product line.
Sourced in United States
The CareLink iPro is a lab equipment product manufactured by Medtronic. It is a continuous glucose monitoring device designed for professional use to collect and analyze glucose data for patients.
Sourced in United States
The FreeStyle Optium Neo® is a blood glucose meter designed for self-monitoring of blood glucose levels. It provides accurate and reliable measurements using a small blood sample.
Sourced in United States
The MiniMed is a compact and portable lab equipment designed for various laboratory applications. It serves as a reliable and versatile tool for researchers and technicians in various scientific fields.
The IPro™2/Enlite™ is a continuous glucose monitoring (CGM) system. It consists of a sensor that is inserted under the skin to measure glucose levels and a small, wearable device that collects and records the glucose data. The system is designed to provide users with real-time glucose information to help manage their diabetes.
Sourced in United States, United Kingdom, Germany, Japan
The FreeStyle Libre is a continuous glucose monitoring system that measures glucose levels in the interstitial fluid. It consists of a small, disposable sensor that is worn on the back of the upper arm and a handheld reader device that can be used to scan the sensor and obtain glucose readings.
Sourced in United States, Japan
JMP v11 is a data analysis software application developed by SAS Institute. It provides a range of statistical and visualization tools for data exploration, modeling, and presentation.
Sourced in United States
The COBAS INTEGRA 400 plus/800 analyzers are clinical chemistry systems designed for routine in-vitro diagnostic testing in a laboratory setting. They are capable of performing a wide range of biochemical and immunochemical assays on various sample types. The analyzers offer automated processing, high throughput, and reliable performance to support efficient laboratory operations.

More about "Blood Glucose Self-Monitoring"

Blood Glucose Monitoring | Continuous Glucose Monitoring | CGM | Blood Sugar Tracking | Diabetes Management | Glucose Sensor | Enlite Sensor | IPro2 | Medisafe Mini | CareLink iPro | FreeStyle Optium Neo® | MiniMed | IPro™2/Enlite™ | FreeStyle Libre | JMP v11 | COBAS INTEGRA 400 plus/800 | Diabetes Care | Glucose Levels | Glycemic Control | Self-Care | Home Testing | Portable Devices | Reproducibility | Accuracy | Informed Decision-Making